Dr. Sorab Gupta
Claim this profileGeisinger Medical Center
Studies Oropharyngeal Carcinoma
Studies Colon Cancer
13 reported clinical trials
24 drugs studied
Area of expertise
1Oropharyngeal Carcinoma
p16 positive
p16 negative
HPV positive
2Colon Cancer
Stage III
MLH1 positive
MSH2 positive
Affiliated Hospitals
Clinical Trials Sorab Gupta is currently running
Pembrolizumab + Radiation vs Chemotherapy + Radiation
for Head and Neck Cancer
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Carboplatin is also in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab alone after surgery may work better than the usual approach in shrinking recurrent or primary head and neck squamous cell carcinoma.
Recruiting1 award Phase 231 criteria
Myopenia
for Colorectal Cancer
This study will examine the association between low muscle mass (myopenia) at diagnosis and chemotherapy toxicity in older adults with newly diagnosed advanced colorectal cancer.
Recruiting1 award N/A6 criteria
More about Sorab Gupta
Clinical Trial Related4 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Sorab Gupta has experience with
- Intensity-Modulated Radiation Therapy
- Cisplatin
- Nivolumab
- Fluorouracil
- Atezolizumab
- Carboplatin
Breakdown of trials Sorab Gupta has run
Oropharyngeal Carcinoma
Colon Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sorab Gupta specialize in?
Sorab Gupta focuses on Oropharyngeal Carcinoma and Colon Cancer. In particular, much of their work with Oropharyngeal Carcinoma has involved p16 positive patients, or patients who are p16 negative.
Is Sorab Gupta currently recruiting for clinical trials?
Yes, Sorab Gupta is currently recruiting for 3 clinical trials in Danville Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Sorab Gupta has studied deeply?
Yes, Sorab Gupta has studied treatments such as Intensity-Modulated Radiation Therapy, Cisplatin, Nivolumab.
What is the best way to schedule an appointment with Sorab Gupta?
Apply for one of the trials that Sorab Gupta is conducting.
What is the office address of Sorab Gupta?
The office of Sorab Gupta is located at: Geisinger Medical Center, Danville, Pennsylvania 17822 United States. This is the address for their practice at the Geisinger Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.